MONOCLONAL ANTIBODIES – BASED CANCER THERAPEUTICS : CURRENT STRATEGIES, RESISTANCE, MECHANISMS, FUTURE PERSPECTIVE

Authors

  • Uppalapati Leela krishna Priyadarshini Institute of Pharmaceutical Education and Research, 5TH Mile, Pulladigunta, Guntur-522017, Andhra Pradesh, India.

Keywords:

Monoclonal Antibodies, Cancer Immunotherapy, Bispecific Antibodies, Antibody- medicine Conjugates, Tumour Microenvironment, Personalized Medicine, Artificial Intelligence in Oncology

Abstract

Monoclonal antibodies( mAbs) have revolutionized oncology by offering  largely specific  remedial options that target tumour associated antigens, minimizing damage to healthy apkins. These biologics  ply their  goods through  colorful mechanisms including receptor  leaguer, vulnerable system modulation, induction of apoptosis, and targeted delivery of cytotoxic agents. The development of coming- generation antibody formats  similar as bispecific antibodies, antibody-  medicine conjugates( ADCs), nanobodies, and  emulsion proteins has further enhanced their  efficacity and broadened clinical  operations. likewise, advances in artificial intelligence( AI) and bioinformatics are paving the way for  individualized antibody- grounded  curatives  acclimatized to individual tumour biographies. Despite their growing clinical  mileage, mAb- grounded  curatives face several challenges that limit their broader  perpetration. These include excrescence  diversity, development of resistance pathways, vulnerable  elusion tactics by cancer cells, limited tumour penetration, and high manufacturing costs. also, adverse  goods  similar as cytokine release pattern and immunogenicity present further clinical hurdles. This review provides a comprehensive overview of monoclonal antibody mechanisms of action, current  remedial strategies, arising  inventions, and the  crucial  natural and logistical challenges encountered in their development and use. unborn directions  punctuate the integration of computational tools for antibody design, combination  curatives with vulnerable checkpoint impediments, and strategies to ameliorate global access and affordability.

Downloads

Download data is not yet available.

References

1. Ponziani S, Di Vittorio G, Pitari G, Cimini AM, Ardini M, Gentile R, et al. Antibody-drug conjugates: the new frontier of chemotherapy. Int J Mol Sci. 2020;21(15):5510. Available from: https://doi.org/10.3390/ijms21155510

2. Zlabinger GJ, Ulrich W, Pohanka E, Kovarik J. OKT 3-Therapie bei Nierentransplantatempfängern [OKT 3 treatment of kidney transplant recipients]. Wien Klin Wochenschr. 1990;102(5):142-147. Available from: https://pubmed.ncbi.nlm.nih.gov/2108521/

3. Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93(3):290-296. Available from: https://doi.org/10.1038/icb.2014.93

4. Zolot RS, Basu S, Million RP. Antibody-drug conjugates. Nat Rev Drug Discov. 2013;12(4):259-260. Available from: https://doi.org/10.1038/nrd3980

5. Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021;14(1):45. Available from: https://doi.org/10.1186/s13045-021-01056-8

6. Fatima I, Rahdar A, Sargazi S, Barani M, Hassanisaadi M, Thakur VK. Quantum dots: synthesis, antibody conjugation, and HER2-receptor targeting for breast cancer therapy. J Funct Biomater. 2021;12(4):75. Available from: https://doi.org/10.3390/jfb12040075

7. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473-480. Available from: https://doi.org/10.1038/nrc2394

8. Modjtahedi H, Ali S, Essapen S. Therapeutic application of monoclonal antibodies in cancer: advances and challenges. Br Med Bull. 2012;104(1):41-59. Available from: https://doi.org/10.1093/bmb/lds032

9. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012;12:14. Available from: https://cancerimmunity.org/journal/view.php?aid=120114

10. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278-287. Available from: https://doi.org/10.1038/nrc3236

11. Little M. Generation, structure, and function of antibodies. In: Little M, editor. Antibodies for Treating Cancer: Basics, Development, and Applications. Cham: Springer International Publishing; 2021. p. 35-46. Available from: https://doi.org/10.1007/978-3-030-80413-8_2

12. Sela-Culang I, Kunik V, Ofran Y. The structural basis of antibody-antigen recognition. Front Immunol. 2013;4:302. Available from: https://doi.org/10.3389/fimmu.2013.00302

13. Megha KB, Mohanan PV. Role of immunoglobulin and antibodies in disease management. Int J Biol Macromol. 2021;169:28-38. Available from: https://doi.org/10.1016/j.ijbiomac.2020.12.073

14. Román VRG, Murray JC, Weiner LM. Antibody-dependent cellular cytotoxicity (ADCC). In: Weiner LM, editor. Antibody Fc. London: Academic Press; 2014. p. 1-27. Available from: https://doi.org/10.1016/B978-0-12-394802-1.00001-3

15. Frenzel A, Kügler J, Helmsing S, Meier D, Schirrmann T, Hust M, et al. Designing human antibodies by phage display. Transfus Med Hemother. 2017;44(5):312-318. Available from: https://doi.org/10.1159/000479633

16. Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. Available from: https://doi.org/10.1186/s12929-019-0592-z

17. Alfaleh MA, Alsaab HO, Mahmoud AB, Alkayyal AA, Jones ML, Mahler SM, et al. Phage display derived monoclonal antibodies: from bench to bedside. Front Immunol. 2020;11:1986. Available from: https://doi.org/10.3389/fimmu.2020.01986

18. Ledsgaard L, Kilstrup M, Karatt-Vellatt A, McCafferty J, Laustsen AH. Basics of antibody phage display technology. Toxins (Basel). 2018;10(6):236. Available from: https://doi.org/10.3390/toxins10060236

19. Almagro JC, Pedraza-Escalona M, Arrieta HI, Pérez-Tapia SM. Phage display libraries for antibody therapeutic discovery and development. Antibodies (Basel). 2019;8(3):44. Available from: https://doi.org/10.3390/antib8030044

20. Valldorf B, Hinz SC, Russo G, Pekar L, Mohr L, Klemm J, et al. Antibody display technologies: selecting the cream of the crop. Biol Chem. 2022;403(5-6):455-477. Available from: https://doi.org/10.1515/hsz-2020-0382

21. Carbone F, Russo C, Colamatteo A, La Rocca C, Fusco C, Matarese A, et al. Cellular and molecular signaling towards T-cell immunological self-tolerance. J Biol Chem. 2024;300(4):107134. Available from: https://doi.org/10.1016/j.jbc.2024.107134

22. Kiranmai M, Renuka P, Brahmaiah B, Chandu BR. Vitamin D as a promising anticancer agent. Int J Res Pharm Chem. 2012;2(2):636-649. Available from: https://www.ijrpc.com/files/12-2108.pdf

23. Girish CH, Vijayalakshmi P, Mentham R, Rao CB, Nama S. A review on breast cancer. Int J Pharma Bio Sci. 2014;4(2):47-54.

24. Rani TT, Brahmaiah B, Revathi B, Nama S, Chandu BR. Targeting of anticancer drugs through nanoparticles. Int J Pharm Ther. 2013;4(3):154-159. Available from: http://www.ijptjournal.com/abstract/targeting-of-anti-cancer-drugs-through-nanoparticles-224.html

25. Pisipati SVV, Pathapati H, Bhukya G, Nuthakki S, Chandu BR, Nama S, et al. Lycopene: redress for prostate cancer. 2013. Available from: https://www.academia.edu/75895370/Lycopene_Redress_for_prostate_cancer

26. Vennela B, Shirisha V, Rao CB, Gullapalli V, Batsala M. Current and future strategies for therapy of pancreatic cancer. Int J Res Pharm Chem. 2012;2(3):728-740. Available from: https://www.ijrpc.com/files/24-2114.pdf

Downloads

Published

2026-06-20

How to Cite

[1]
Uppalapati, L.K. 2026. MONOCLONAL ANTIBODIES – BASED CANCER THERAPEUTICS : CURRENT STRATEGIES, RESISTANCE, MECHANISMS, FUTURE PERSPECTIVE. Journal of Drug Reactions. 2, 2 (Jun. 2026), 10–14.

Issue

Volume 2, Issue 2, 2026

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.